Prioritizing targets for precision cancer medicine

Area of Science:

• Oncology
• Genomics
• Clinical Trials

Background:

• Cancer genomic testing is increasingly used in clinical settings, presenting new opportunities.
• Advances in cancer genomics reveal complexities in identifying driver mutations and classifying therapeutic targets.
• Understanding clonal and sub-clonal structures is crucial for effective cancer treatment.

Purpose of the Study:

• To review current insights into cancer genomic testing in clinical practice.
• To propose a novel target classification approach for prioritizing tumor drivers.
• To address challenges in driver identification and target classification.

Main Methods:

• Literature review of recent advancements in cancer genomic testing.
• Analysis of evidence supporting the prioritization of tumor drivers for therapeutic targeting.
• Consideration of complex cancer clonal structures and clinical outcomes.

Main Results:

• Current understanding highlights significant challenges in driver identification and target classification.
• A proposed classification system considers evidence levels for prioritizing tumor drivers.
• Complex clonal structures and clinical data influence therapeutic targeting strategies.

Conclusions:

• A structured classification approach is needed to navigate the complexities of cancer genomic testing.
• Transparent reporting of clinical data (positive and negative) is essential for balanced evaluation.
• Further research into sub-clonal dynamics will optimize patient consent and clinical trial design.